Literature DB >> 33466908

Mood and Metabolic Health Status of Elderly Osteoporotic Patients in Korea: A Cross-Sectional Study of a Nationally Representative Sample.

Hyen Chul Jo1,2, Gu-Hee Jung2,3,4, Seong-Ho Ok2,5, Ji Eun Park1,2, Jong Chul Baek1,2.   

Abstract

This study aimed to investigate the association between osteoporosis and comorbidity, which are very common in Korea, and develop a treatment strategy to improve bone health based on the findings of the Korean National Health and Nutritional Examination Surveys (KNHANES). This study was based on data obtained from 4060 subjects (1755 males, 2305 females) aged above 60 years in the KNHANES (2016-2017). Well-trained medical staff performed the standard procedures and measured several variables including height, weight, and waist circumference. Interviews and laboratory tests were based on the diagnosis of hyperuricemia, dyslipidemia, type 2 diabetes mellitus (T2DM), osteoporosis, and depression. Comorbidities were defined as a self-reported physician diagnosis. The association of osteoporosis with depression and metabolic disease was assessed statistically using the complex sample analysis method of SPSS. The presence of osteoporosis, dyslipidemia, T2DM, hyperuricemia, obesity, abdominal obesity, and depression was 6.1 ± 0.5%, 15.2 ± 0.7%, 6.5 ± 0.4%, 13.4 ± 0.7%, 30.8 ± 0.8%, 19.4 ± 0.9%, 4.0 ± 0.2%, respectively. After adjusted by age, osteoporotic subjects were significance in the presence of abdominal obesity (p = 0.024, OR 0.80), hyperuricemia (p = 0.013, OR 0.68), dyslipidemia (p < 0.001, OR 1.84), and depression (p < 0.001, OR 2.56), respectively. Subgroup analyses showed dyslipidemia (female subjects, p < 0.001, OR 1.04; male subjects, p = 0.94, OR 1.09) and depression (female subjects, p < 0.001, OR 1.76; male subjects, p = 0.51, OR 0.62) were associated with osteoporotic female subjects but not in male subjects. The comorbidity of dyslipidemia and depression in female subjects was associated with osteoporosis and an odds ratio was 13.33 (95% CI: 8.58-20.71) (p < 0.001). The comorbidity of abdominal obesity (female subjects, p = 0.75, OR 0.97; male subjects, p = 0.94, OR 1.02) and hyperuricemia (female subjects, p = 0.27, OR 0.81; male subjects p = 0.07, OR 0.35) was not associated with osteoporosis in both Subgroup. The result of this study shows a strong dependency of comorbidity with dyslipidemia and depression in elderly women with osteoporosis. Therefore, efforts to improve dyslipidemia and depression might prevent compromised bone health.

Entities:  

Keywords:  abdominal obesity; depression; dyslipidemia; elderly; hyperuricemia; osteoporosis

Year:  2021        PMID: 33466908      PMCID: PMC7830950          DOI: 10.3390/healthcare9010077

Source DB:  PubMed          Journal:  Healthcare (Basel)        ISSN: 2227-9032


  38 in total

Review 1.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

Authors: 
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

Review 2.  Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis.

Authors:  Nicola Veronese; Sara Carraro; Giulia Bano; Caterina Trevisan; Marco Solmi; Claudio Luchini; Enzo Manzato; Riccardo Caccialanza; Giuseppe Sergi; Davide Nicetto; Emanuele Cereda
Journal:  Eur J Clin Invest       Date:  2016-10-05       Impact factor: 4.686

3.  Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men.

Authors:  Ha Young Kim; Jae Won Choe; Hong Kyu Kim; Sung Jin Bae; Beom Jun Kim; Seung Hun Lee; Jung-Min Koh; Ki Ok Han; Hyoung Moo Park; Ghi Su Kim
Journal:  Calcif Tissue Int       Date:  2010-03-31       Impact factor: 4.333

4.  Association between depression and metabolic syndrome in korean women: Results from the korean national health and nutrition examination survey (2007-2013).

Authors:  Se Jin Park; Sungwon Roh; Jaemin Hwang; Hyoung Ah Kim; Sohye Kim; Tae Kyung Lee; Shi Hyun Kang; Yu Jeong Ha; Jung Won Jang; Subin Park
Journal:  J Affect Disord       Date:  2016-08-16       Impact factor: 4.839

5.  Low bone mineral density is associated with dyslipidemia in South Korean men: the 2008-2010 Korean National Health and Nutrition Examination Survey.

Authors:  Yang-Hyun Kim; Ga-Eun Nam; Kyung-Hwan Cho; Youn Seon Choi; Seon-Mee Kim; Byung-Duck Han; Kyung Do Han; Kyung-Shik Lee; Chang-Hae Park; Do-Hoon Kim
Journal:  Endocr J       Date:  2013-07-23       Impact factor: 2.349

6.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

7.  Factors Associated with a Low-sodium Diet: The Fourth Korean National Health and Nutrition Examination Survey.

Authors:  Won Joon Lee; Hyeon Chang Kim; Sun Min Oh; Dong Phil Choi; Jaelim Cho; Il Suh
Journal:  Epidemiol Health       Date:  2013-06-20

Review 8.  Obesity, Type 2 Diabetes and Bone in Adults.

Authors:  Jennifer S Walsh; Tatiane Vilaca
Journal:  Calcif Tissue Int       Date:  2017-03-09       Impact factor: 4.333

9.  Effects of metabolic syndrome on bone mineral density, histomorphometry and remodelling markers in male rats.

Authors:  Sok Kuan Wong; Kok-Yong Chin; Farihah Hj Suhaimi; Fairus Ahmad; Soelaiman Ima-Nirwana
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

10.  Association between metabolic syndrome and osteoporosis in Taiwanese middle-aged and elderly participants.

Authors:  Hsin-Hui Lin; Chun-Yuan Huang; Lee-Ching Hwang
Journal:  Arch Osteoporos       Date:  2018-04-28       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.